J9250 — Methotrexate sodium, 5 mg
J9250 is a HCPCS Level II code for methotrexate sodium, 5 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on March 31, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated J9250 on March 31, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9250
- Long descriptor
- Methotrexate sodium, 5 mg
- Short descriptor
- Methotrexate sodium inj
- Added
- January 1, 1994
- Terminated
- March 31, 2024
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9250
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9250 is not quite right, the correct code is very often within a few positions of it.
- J9229Injection, inotuzumab ozogamicin, 0.1 mg
- J9230Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg
- J9232Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg
- J9245Injection, melphalan hydrochloride, not otherwise specified, 50 mg
- J9246Injection, melphalan (evomela), 1 mg
- J9247Injection, melphalan flufenamide, 1mgterminated
- J9248Injection, melphalan (hepzato), 1 mg
- J9249Injection, melphalan (apotex), 1 mg
- J9255Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg
- J9256Injection, nipocalimab-aahu, 3 mg
- J9258Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mgterminated
- J9259Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mgterminated
- J9260Injection, methotrexate sodium, 50 mg
- J9261Injection, nelarabine, 50 mg
- J9262Injection, omacetaxine mepesuccinate, 0.01 mg
- J9263Injection, oxaliplatin, 0.5 mg
Questions about J9250
What is HCPCS code J9250?
J9250 is a HCPCS Level II code for methotrexate sodium, 5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9250?
The CMS HCPCS file marks J9250 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is J9250 still valid?
No. J9250 was terminated on March 31, 2024 and should not be used on new claims.